In order to identify novel targets in pancreatic cancer cells, we utilized high-throughput RNAi 26 
Introduction 43
Pancreatic cancer is one of the most aggressive and lethal cancers known today, with a 5-44 year survival of only 4%. In 2009, pancreatic cancer was the fourth-leading cause of cancer-45 related deaths (1). Patients diagnosed with pancreatic cancer typically have a poor prognosis due 46 to a lack of early symptoms, leading to metastatic disease at the time of diagnosis. The treatment 47 options for pancreatic cancer include chemotherapy, surgery and radiation. The most preferred 48 current therapeutic drug to treat pancreatic cancer is gemcitabine, yet the one-year survival of 49 pancreatic cancer patients treated with gemcitabine is about 18%, representing a significant but 50 modest advancement in the quality of life (2). Clearly, novel targets and therapeutic 51 combinations are needed to more effectively treat patients afflicted with this deadly disease. 52
Previously, our laboratory has reported on the use of a high-throughput RNA interference 53 (HT-RNAi) platform to identify potential sensitizing targets to gemcitabine in pancreatic cancer 54 cells (3) and to cisplatin in ovarian cancer (4). This procedure utilized a library of small 55 interfering RNA (siRNA) to identify functional mediators of the cytotoxic response to 56 chemotherapeutic agents. This HT-RNAi screen is also capable of identifying targets which, 57 when silenced, would cause a decrease in cancer cell viability in the absence of additional 58 therapeutics as previously reported (5). The targets identified by these types of HT-RNAi 59 screens are referred to as Achilles' Heel (AH) targets. In the current study, we have utilized this 60 HT-RNAi platform to identify novel AH targets in pancreatic cancer, using BxPC3 cells. One 61 novel AH target identified from this screen was tyrosine non-receptor kinase 1 (TNK1). 62 TNK1 was first identified in human umbilical cells (6) and murine embryonic stem cells 63 as a tumor suppressor that downregulates Ras activity (7). It was further determined that TNK1 64 knockout mice form spontaneous tumors (8) and TNK1 blocks NFκB activation to facilitate 65 as an indicator of successful transfection for each plate. The screening data was normalized 115 using the standard z-score method by correcting the raw data for plate row variation, and then 116 normalizing and pooling data from all assay plates. The assumption is that the majority of the 117 siRNAs are non-hits and the null distribution is normal (15). The criteria for identification of 118 potential hits were z-score values of less than -1.65, which corresponded to a p-value of 0.05, in 119 at least three of the four screens of pancreatic cancer cells. This cutoff was chosen due to the 120 relatively small size and focused nature of the screen. Validation of screening results with a 121 panel of pancreatic cancer cell lines was done in a similar assay format. 122
123

Dose response assays 124
Cells were reverse transfected as described above in 384-well plates and incubated with 125 siRNA (Qiagen) for 24 hours. Gemcitabine was added at a range of concentrations and cells 126 were incubated for a further 72 hours. Cell viability was measured as described above. Drug-127 dose response curves were generated and IC 50 Cells were reverse-transfected with siRNA in 6-well plates and incubated for 24-72 160 hours. Total RNA was collected using a RNeasy MiniPrep Kit (Qiagen) and concentration was 161 measured using a Nano Drop (Thermo Scientific; Wilmington, DE). cDNA was generated using 162 an iScript cDNA synthesis Kit (Bio-Rad). Primers for TNK1 were purchased from Qiagen. 163
Samples were run in triplicate on a 96-well PCR plate using an Opticon 2 (MJ Research, 164
Waltham, MA). All samples were normalized to levels of GAPDH. viability was assessed using a luminescence-based cell number assay and the data were 174 normalized and analyzed as described in Materials and Methods. Two independent HT-RNAi 175 screens were conducted in order to produce a biological replicate of the results. Data was 176 normalized by z-score analysis and results are shown as the z-score for each kinase siRNA in 177 each screen of the BxPC3 cells as well as previous screens using MiaPaCa-2 cells (Fig. 1A) . 178
Hits were designated as having z-scores lower than -1.65 for at least three out of the four assays 179 on the pancreatic cell lines. These criteria identified 32 kinases as significant in growth of both 180
BxPC3 and MiaPaCa-2 cells (Fig. 1B and Supplemental Table S2 ). Furthermore, comparison of 181 these hits to z-scores from a HT-RNAi kinase screen done on the normal fibroblasts cell line 182 GM05659 showed 22 kinase targets that did not overlap and thus seem to be specific for the 183 pancreatic cancer cells (Table 1) . Several of these kinases have previously been associated with 184 growth and survival of pancreatic cancer cells. One kinase identified as a hit in both cell lines 185 was TNK1, which was the focus of subsequent studies due to reports that it had both tumor 186 suppressor and oncogenic properties. To demonstrate the silencing efficiency of the siRNA targeting TNK1, MiaPaCa-2 and 190
BxPC3 cells were transfected with TNK1 or non-silencing siRNA and incubated at 37˚C for 72 191 hours. For these validation experiments, we utilized three different siRNA sequences of which 192 two of these sequences were identical to the ones used in the initial. Total RNA was collected 193 and cDNA was generated to determine levels of TNK1 mRNA by qRT-PCR. Additionally, cell 194 lysates were analyzed by western blot using an anti-TNK1 antibody. Results using show that all three TNK1 siRNA sequences tested were able to reduce the TNK1 message levels 196 compared to non-silencing siRNA ( Fig. 2A) . Furthermore, silencing of TNK1 resulted in 197 decreased TNK1 protein level as demonstrated by the western blot results (Fig. 2B) . (Fig. 3A) . We further quantified TNK1 protein expression levels using densitometry 206 analysis (Fig. 3B) To determine if TNK1 knockdown affected SMAD4 expression, we treated Panc-1 cells 217 with TNK1 or non-silencing siRNA and analyzed SMAD4 expression by western blot (Fig. 3C) . To test for expression of activated TNK1, we first immunoprecipitated whole cell lysates 236 using a bead-bound p-Tyr antibody. Blotting with a TNK1 antibody revealed high levels of 237 phosphorylated TNK1 in BxPC3 and CAPAN-1 cells (Fig. 4C) . These samples were also blotted 238 with a phospho-TNK1 antibody specific for the Tyr 277 residue. We note that CAPAN-1, 239 CAPAN-2, and HPAC cells all demonstrate high levels of phosphorylation at this particular 240 residue. In contrast, we did not observe any phosphorylation of TNK1 in the normal pancreatic 241 epithelial cell line HPDE6. 
Discussion 272
In this study, we used HT-RNAi screening to identify kinases whose silencing decreased 273 growth of pancreatic cancer cells. Furthermore, we validated the kinase TNK1 as a novel 274 pancreatic cancer target important in cell growth and survival. HT-RNAi screens with a kinase 275 siRNA library on the BxPC3 and MiaPaCa-2 pancreatic cancer cell lines (Fig. 1) identified 32  276 kinases as being important in cell growth of pancreatic cancer cells (Table 1 ). Of these, 22 277 kinases appeared to be specific for the pancreatic cancer cells compared to a previous HT-RNAi 278 kinase dataset from normal fibroblasts. Although several of the kinases have been previously 279 associated with cancer (i.e. p38, CALM1, HK1, STK10), we focused on TNK1 in this study due 280 to previous studies suggesting both tumor suppressor and oncogenic activity (8, 11). 281 TNK1 was identified as a hit in both the MiaPaCa-2 and BxPC3 siRNA screens and has 282 not been previously associated with pancreatic cancer. Expression analysis of TNK1 in a panel 283 of pancreatic cells showed only slight variations in levels of TNK1 expression with the highest 284 expression seen in HPAC cells (Fig. 2C) . While protein expression levels are relatively low 285 overall, we did note the presence of phosphorylated TNK1 in several pancreatic cell lines (Fig.  286 2A and 2B). Silencing of TNK1 by siRNA reduced the cell viability of several pancreatic cell 287 lines and induced apoptosis (Figs. 4A and B) . Furthermore, TNK1 knockdown affected cell 288 survival by potentiating gemcitabine-induced cytotoxicity (Figs. 5A and B) . 289
Though all cell lines demonstrate a statistically significant decrease in viability when 290 treated with TNK1 siRNA, Panc-1 and AsPC-1 were noticeably less affected than the BxPC3, 291
MiaPaCa-2, and Su.86.86 cell lines. While the exact nature of this observation is unclear, we do 292 note that cell lines exhibiting a mesenchymal phenotype tend to demonstrate lower expression of 293 TNK1 than those with epithelial characteristics (Fig. 3A) . These data combined with the 294 
